Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000287848 encodes a long non-coding RNA termed "novel transcript, antisense to AKR1C4" (also known as AL355303.2), transcribed in the antisense orientation relative to the protein-coding gene AKR1C4[3][9]. Antisense lncRNAs such as this are known to regulate gene expression, often by influencing the transcription, processing, or stability of the corresponding sense mRNA through mechanisms related to chromatin modification and transcriptional interference[2][4][6]. While global studies demonstrate that antisense transcription can modulate chromatin structure and sense transcript dynamics, there is no direct evidence linking this specific lncRNA to a distinct gene regulatory or disease role, nor is it currently regarded as a therapeutic target. Its main significance may lie in the broader biological context of antisense RNA regulation rather than as an individual druggable entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to AKR1C4 (ENSG00000287848).